Virginia Oncology Associates

Newport News, Virginia 23606

6 studies enrolling now · 41 studies all time

What they study most

Advanced, Androgen Receptor Positive Triple Negative Breast Cancer, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Brain Metastases, Breast Cancer, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Castration-Resistant Prostate Cancer, Colorectal Cancer, Early Breast Cancer, Esophageal Adenocarcinoma, Extensive-Stage Small-Cell Lung Cancer

Studies at this site

• Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer — Recruiting now
• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) — Recruiting now
• Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer — Recruiting now
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
• MYLUNG Consortium Part 3: Observational Study — Recruiting now
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer — Recruiting now
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors — Completed
• An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Running, not enrolling
• MYLUNG Consortium Study Protocol 2 — Running, not enrolling
• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression — Completed
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Running, not enrolling
• RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases — Stopped early
• Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer — Completed
• A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) — Completed
• Breast Cancer Index (BCI) Registry — Running, not enrolling
• Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) — Completed
• A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer — Completed
• NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial — Stopped early
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
• A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer — Completed
• A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) — Completed
• Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer — Stopped early
• Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer — Completed
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer — Completed
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed
• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy — Completed
• Phase 1 and 2 Study of PX-866 and Cetuximab — Completed
• Study of PX-866 and Docetaxel in Solid Tumors — Completed
• Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer — Stopped early
• A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer — Completed
• Efficacy Study of ABR-215050 to Treat Prostate Cancer — Completed
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors — Completed
• Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma — Stopped early
• Triple Negative Breast Cancer Biomarker Study — Completed
• A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain — Stopped early
• Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer — Completed
• Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma — Completed
• Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer — Completed
• Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) — Stopped early
• A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients — Completed
• Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed — Completed